Xia Anyue, Liu Jinliang, Tang Cuilan, Xu Huan
Department of Infectious Diseases, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, PR China.
Department of Clinical Laboratory Medicine, General Hospital of Xizang Military Command, Lhasa 850000, PR China.
IDCases. 2025 May 9;40:e02249. doi: 10.1016/j.idcr.2025.e02249. eCollection 2025.
Sofosbuvir, a pan-genotypic antiviral agent, has emerged as a cornerstone in the treatment of chronic hepatitis C, offering significant efficacy. Despite its established therapeutic benefits, the drug's safety profile and the occurrence of adverse reactions are less documented due to its recent introduction to the market. Here we report a patient who experienced drug-induced eruption induced by two distinct sofosbuvir-containing regimens. The report includes a thorough analysis and discussion of the case, accompanied by a comprehensive literature review.
索磷布韦是一种泛基因型抗病毒药物,已成为慢性丙型肝炎治疗的基石,具有显著疗效。尽管其治疗益处已得到确立,但由于该药最近才进入市场,其安全性和不良反应的发生情况记录较少。在此,我们报告一名患者,其因两种不同的含索磷布韦方案诱发了药物性皮疹。本报告包括对该病例的深入分析和讨论,并伴有全面的文献综述。